Gastroenterology

Scientists at the Task Force for Global Health describe what is needed to eliminate HBV and HCV as public health threats.

Models indicate that a vaccine with just 30% efficacy would significantly reduce HCV transmission if provided to persons at high risk of infection from injecting drugs.

First prospective study of direct-acting antiviral treatment of HCV in cancer patients finds that it is safe, efficacious, and that it can open options for chemotherapy.

Researchers calculate universal HCV screening of pregnant women would be cost-effective in the US, including in states with low HCV prevalence.

Analysis of multiple studies demonstrates glecaprevir/pibrentasvir pangenotypic HCV efficacy despite concurrent gastric acid-reducing drugs.

The new guideline centers on the overall diagnosis, management, and clinical treatment of the chronic inflammatory disease.

Direct-acting antiviral treatment of HCV prior to liver transplant does not increase pre-transplant liver cancer progression or post-transplant recurrence.

The first prospective, longitudinal study of direct-acting antivirals for HCV finds that treatment reduces risks of all-cause mortality and liver cancer.

A novel method to inactivate HCV in donor lungs could allow additional transplants without post-transplant antiviral treatment.

Successful HCV treatment with direct-acting antivirals provides long-term efficacy in resolving HCV-associated cryoglobulinemia vasculitis.

Sustained virologic response was achieved regardless of the hepatitis C genotype.

Universal screening for HCV infection is projected to be cost effective and provide greater benefit than the currently recommended birth cohort screening.

Despite virologic cures of hepatitis C with direct-acting antivirals, post-cure care is necessary to prevent liver disease progression and manage complications.

For 2 years after C difficile infection, patients under 65 years were at greater risk for gastrointestinal diagnoses compared to uninfected patients.

Investigators hope their findings will alleviate clinicians’ concerns about choosing between fidaxomicin and oral vancomycin for treatment.

New host-targeting agents might help to overcome challenges in treating hepatitis C that remain, despite success with direct-acting antivirals.

Investigators are now interested in assessing potential benefits of direct-acting antivirals for HCV patients who previously had liver cancer.

Three newly discovered strains of HCV genotype 7 in Africa, and a genotype 8 in India, complicate the World Health Organization's goal to eradicate HCV.

Novel epidemiological approach accounting for persons with undiagnosed HCV shows half of cases in US are in 9 states, including 5 in Appalachia.

Currently in phase 1 testing, ACX-362E is being developed as a narrow spectrum antibiotic for the treatment of Clostridium difficile infection.

Success with metronidazole was more likely in patients 65 years and under but was about the same as with vancomycin in those patients.

Mapping techniques for tracking sexually transmitted bacterial disease can also identify core areas of HCV infection to guide treatment interventions.

The new C difficile guidelines highlight improvements in diagnosing the condition and treating with newer options like fidaxomicin, vancomycin, and fecal microbiota transplantation.

Analysis of data from phase 2 and 3 trials supports an HCV genotype 3 indication for glecaprevir/pibrentasvir, and confirms its efficacy over 8 weeks.

Researchers studied patients with hepatitis C in order to find out the relationship between immune activation and chronic fatigue.